Home / World Marketplace / Archive by category Global Health & Biotech (Page 42)

Archive by category Global Health & Biotech

Junshi Biosciences Announces Commercialization Partnership with LEO Pharma for Toripalimab in Europe

SHANGHAI, Jan. 20, 2025 (Korea Bizwire) – Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, and its wholly-owned subsidiary, TopAlliance Biosciences Inc. (TopAlliance Biosciences), announced a distribution and marketing partnership with LEO Pharma for toripalimab in Europe. [...]

Junshi Biosciences Announces Toripalimab’s Approval in Australia

SHANGHAI, Jan. 17, 2025 (Korea Bizwire) – Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, and its wholly-owned subsidiary, TopAlliance Biosciences Inc. (TopAlliance Biosciences), announced that toripalimab, the anti-PD-1 monoclonal antibody self-developed by the company, has obtained [...]

Boehringer provides update on iclepertin Phase III program in schizophrenia

Boehringer Ingelheim today announced top-line results from the Phase III CONNEX clinical program in cognitive impairment in adults with schizophrenia, showing primary and key secondary endpoints were not met.1–6 Overall, no statistically significant effects on cognition or functioning were observed in patients treated with iclepertin versus placebo at six months.1 All three trials demonstrated that iclepertin, a [...]

Smith+Nephew’s ALLEVYN™ LIFE Sacrum Foam Dressing and LEAF™ Patient Monitoring System receive ‘favorable’ Evidence Bar™ ratings from ECRI for pressure injury prevention

Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces that ECRI – leaders in advancing evidence-based healthcare globally – have completed updated Clinical Evidence Assessments of ALLEVYN LIFE Sacrum Foam Dressings and the LEAF Patient Monitoring System. In their latest reports, ECRI upgraded its Evidence Bar ratings for both to favorable* after assessing the most [...]

Sandoz to confirm strategic roadmap and highlight pipeline catalysts at 43rd Annual J.P. Morgan Healthcare Conference

Strong first year as standalone company; global leader Sandoz uniquely positioned in attractive and growing USD 200 billion market for generics and biosimilars Leading in home market Europe, which represents half of total sales; strategically positioning company to become #1 in biosimilars in US, with three US launches expected in 2025 Ambitious GLP-1 strategy in [...]

Avance Clinical Leads as the CRO of Choice for Early Phase Clinical Trials in Australia – Announced at Biotech Showcase 2025

WAKE FOREST, N.C. and ADELAIDE, Australia, Jan. 13, 2025 (Korea Bizwire) – Avance Clinical, a leading full-service global Contract Research Organization (CRO) known for delivering high-quality, agile clinical research services, is proud to announce it is the CRO of choice for early phase clinical trials in Australia with more than 52% of market share. Avance Clinical [...]

Carestream Health Continues Innovation with Powerful Improvements to Trailblazing DRX-Revolution Mobile X-ray System

Rochester, N.Y., Jan. 13, 2025 (Korea Bizwire) – Carestream Health, a leading provider of medical imaging solutions, announced today the addition of new features to its popular DRX-Revolution Mobile X-ray System. These new features continue Carestream’s tradition of innovative, mobile imaging excellence to help improve efficiency, ease of use, and image quality. The DRX-Revolution Mobile [...]

Teva Announces Collaboration to Commercialize Formycon’s Biosimilar Candidate to Eylea® (aflibercept) in major parts of Europe and in Israel

Klinge Biopharma GmbH (Klinge) holds the exclusive global commercialization rights for FYB203, Formycon’s biosimilar candidate to Eylea®1 Agreement builds on the proven and successful collaboration of commercialization of FYB201, Formycon’s biosimilar to Lucentis®2 (ranibizumab) in Europe The partnership broadens Teva’s biosimilars portfolio, in line with its Pivot to Growth strategy TEL AVIV, Israel, Jan. 13, 2025 [...]

Samsung Bioepis and Teva Enter into a Strategic Partnership for Commercialization of EPYSQLI® (eculizumab-aagh) in the United States

Marks a step forward in broadening treatment options for patients with paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS) and generalized myasthenia gravis (gMG) in the U.S. Partnership supports Teva’s Pivot to Growth strategy and adds to its broad biosimilar portfolio INCHEON, Korea and TEL AVIV, Israel, Jan. 10, 2025 (Korea Bizwire) – Samsung Bioepis Co., Ltd. and Teva Pharmaceutical Industries Ltd. [...]

Philips appoints Jie Xue as Chief Business Leader Precision Diagnosis, co-leader of the Diagnosis & Treatment segment, and Özlem Fidanci as Chief of International Region

January 9, 2025 Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced the appointment of Jie Xue as Chief Business Leader Precision Diagnosis, and Özlem Fidanci as Chief of International Region, both effective January 1, 2025. Ms. Xue and Ms. Fidanci have joined Philips’ Executive Committee and report directly [...]